1228559-00-9 Usage
General Description
(1S)-1-(4-Bromo-2-fluorophenyl)ethylamine is a chemical compound that belongs to the class of phenethylamine derivatives. It is an organic compound that consists of a benzene ring with a bromine and fluorine atom attached to it, along with an ethylamine group. (1S)-1-(4-BROMO-2-FLUOROPHENYL)ETHYLAMINE has several potential uses, including in the pharmaceutical industry for the synthesis of various drugs, and in research as a starting material for the preparation of other compounds. The presence of a bromine and fluorine atom in its structure gives it some unique chemical properties, making it of interest to scientists and researchers for various applications. Additionally, this chemical has the potential to be used as a building block for the synthesis of more complex organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1228559-00-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,5,5 and 9 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1228559-00:
(9*1)+(8*2)+(7*2)+(6*8)+(5*5)+(4*5)+(3*9)+(2*0)+(1*0)=159
159 % 10 = 9
So 1228559-00-9 is a valid CAS Registry Number.
1228559-00-9Relevant articles and documents
3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
-
Page/Page column 158; 159; 172, (2014/09/29)
The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
CB1 RECEPTOR MODULATORS
-
Page/Page column 52, (2008/12/06)
Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention
